Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI (LP)

IVI Madrid

Status: Completed

Conditions: Infertility

Treatments: Drug: Ganirelix

Study type: Observational

Funder types: Other

Identifiers

NCT00780858

IVIMAD-JMS-09-2008-02

Details and patient eligibility

About

Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

Full description

The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who

Enrollment: 662 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• previous failed IUI cycle with premature luteinization

Exclusion criteria

• 39 years or older
• not eligible for IUI (patent tubes, > 3 million capacitated spermatozoa)
• 4 previous IUI cycles

Trial design

662 participants in 2 patient groups

Ganirelix

Description:

Patients with premature lutenization (progesterone \>1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.

Treatment:

Drug: Ganirelix

Control

Description:

Patients without premature lutenization (progesterone \>1,2 ng/ml) underwent a only one IUI.